Novel Amino Pyrimidine Derivatives

Abstract

The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.

1 . A method of treating a disease which is treated by the modulation of Btk, wherein the method comprising administration of a therapeutically acceptable amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, 
       
         
           
           
               
               
           
         
         wherein,
 R1 is hydrogen, C 1 -C 6  alkyl optionally substituted by hydroxy; 
 R2 is hydrogen or halogen; 
 R3 is hydrogen or halogen; 
 R4 is hydrogen; 
 R5 is hydrogen or halogen; 
 or R4 and R5 are attached to each other and stand for a bond, —CH 2 —, —CH 2 —CH 2 , —CH═CH—, —CH═CH—CH 2 —; —CH 2 —CH═CH—; or —CH 2 —CH 2 —CH 2 —; 
 R6 and R7 stand independently from each other for H, C 1 -C 6  alkyl optionally substituted by hydroxyl, C 3 -C 6  cycloalkyl optionally substituted by halogen or hydroxy, or halogen; 
 R8, R9, R, R′, R10 and R11 independently from each other stand for H, or C 1 -C 6  alkyl optionally substituted by C1-C6 alkoxy; or any two of R8, R9, R, R′, R10 and R11 together with the carbon atom to which they are bound may form a 3-6 membered saturated carbocyclic ring; 
 R12 is hydrogen or C 1 -C 6  alkyl optionally substituted by halogen or C 1 -C 6  alkoxy; 
 or R12 and any one of R8, R9, R, R′, R10 or R11 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C 1 -C 6  alkyl or C 1 -C 6  alkoxy; 
 n is 0 or 1; and 
 R13 is C 2 -C 6  alkenyl optionally substituted by C 1 -C 6  alkyl, C 1 -C 6  alkoxy or N,N-di-C 1 -C 6  alkyl amino; C 2 -C 6  alkynyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy; or C 2 -C 6  alkylenyl oxide optionally substituted by C 1 -C 6  alkyl, 
 
         and wherein the disease is selected from asthma, rheumatoid arthritis, systemic onset juvenile idiopathic arthritis, gout, pemphigus vulgaris, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjögren's syndrome, autoimmune hemolytic anemia, anti-neutrophil cytoplasmic antibodies associated vasculitides, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, atopic dermatitis, contact dermatitis, allergic rhinitis, atherosclerosis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, ulcerative colitis, morbus Crohn, pancreatitis, glomerolunephritis, Goodpasture's syndrome, Hashimoto's thyroiditis, Grave's disease, antibody-mediated transplant rejection, graft versus host disease, B cell-mediated hyperacute, and acute and chronic transplant rejection. 
       
     
     
         2 . The method of  claim 1 , wherein
 R1 is hydrogen, or C 1 -C 6  alkyl optionally substituted by hydroxy;   R2 is halogen;   R3 is hydrogen;   R4 is hydrogen;   R5 is halogen;   or R4 and R5 are attached to each other and stand for a bond, —CH 2 —, —CH 2 —CH 2 —, —CH═CH—, —CH═CH—CH 2 —; —CH 2 —CH═CH—; or —CH 2 —CH 2 —CH 2 —;   R6 and R7 stand independently from each other for H, C 1 -C 6  alkyl optionally substituted by hydroxyl, C 3 -C 6  cycloalkyl optionally substituted by halogen or hydroxy, or halogen;   R8, R9, R10 and R11 independently from each other stand for H, or C 1 -C 6  alkyl; or any two of R8, R9, R10 and R11 together with the carbon atom to which they are bound may form a 3-6 membered saturated carbocyclic ring;   R and R′ are hydrogen;   R12 is hydrogen or C 1 -C 6  alkyl optionally substituted by halogen;   or R12 and any one of R8, R9, R, R′, R10 or R11 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C 1 -C 6  alkyl or C 1 -C 6  alkoxy;   n is 0 or 1; and   R13 is C 2 -C 6  alkenyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy; C 2 -C 6  alkynyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy; or C 2 -C 6  alkylenyl oxide optionally substituted by C 1 -C 6  alkyl.   
     
     
         3 . The method of  claim 1 , wherein
 R1 is hydrogen, or C 1 -C 6  alkyl optionally substituted by hydroxy;   R2 is halogen;   R3 is hydrogen;   R4 is hydrogen;   R5 is halogen;   R6 and R7 stand independently from each other for H, C 1 -C 6  alkyl optionally substituted by hydroxyl, C 3 -C 6  cycloalkyl optionally substituted by halogen or hydroxy, or halogen;   R8, R9, R10 and R11 independently from each other stand for H, or C 1 -C 6  alkyl; or any two of R8, R9, R10 and R11 together with the carbon atom to which they are bound may form a 3-6 membered saturated carbocyclic ring;   R and R′ are hydrogen;   R12 is hydrogen or C 1 -C 6  alkyl optionally substituted by halogen;   or R12 and any one of R8, R9, R, R′, R10 or R11 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C 1 -C 6  alkyl or C 1 -C 6  alkoxy;   n is 0 or 1; and   R13 is C 2 -C 6  alkenyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy; C 2 -C 6  alkynyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy; or C 2 -C 6  alkylenyl oxide optionally substituted by C 1 -C 6  alkyl.   
     
     
         4 . The method of  claim 1 , wherein
 R1 is hydrogen, C 1 -C 6  alkyl optionally substituted by hydroxy;   R2 is hydrogen or halogen;   R3 is hydrogen or halogen;   R4 and R5 are attached to each other and stand for a bond, —CH 2 —, —CH 2 —CH 2 —, —CH═CH—, —CH═CH—CH 2 —; —CH 2 —CH═CH—; or —CH 2 —CH 2 —CH 2 —;   R6 and R7 stand independently from each other for H, C 1 -C 6  alkyl optionally substituted by hydroxyl, C 3 -C 6  cycloalkyl optionally substituted by halogen or hydroxy, or halogen;   R8, R9, R10 and R11 independently from each other stand for H, or C 1 -C 6  alkyl; or any two of R8, R9, R10 and R11 together with the carbon atom to which they are bound may form a 3-6 membered saturated carbocyclic ring;   R and R′ are hydrogen;   R12 is hydrogen or C 1 -C 6  alkyl optionally substituted by halogen;   or R12 and any one of R8, R9, R, R′, R10 or R11 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C 1 -C 6  alkyl or C 1 -C 6  alkoxy;   n is 0 or 1; and   R13 is C 2 -C 6  alkenyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy; C 2 -C 6  alkynyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy; or C 2 -C 6  alkylenyl oxide optionally substituted by C 1 -C 6  alkyl.   
     
     
         5 . The method of  claim 1 , wherein
 R1 is hydrogen, C 1 -C 6  alkyl optionally substituted by hydroxy;   R2 is hydrogen or halogen;   R3 is hydrogen or halogen;   R4 and R5 are attached to each other and stand for a —CH 2 —CH 2 —, or —CH═CH—;   R6 and R7 stand independently from each other for H, C 1 -C 6  alkyl optionally substituted by hydroxyl, C 3 -C 6  cycloalkyl optionally substituted by halogen or hydroxy, or halogen;   R8, R9, R10 and R11 independently from each other stand for H, or C 1 -C 6  alkyl; or any two of R8, R9, R10 and R11 together with the carbon atom to which they are bound may form a 3-6 membered saturated carbocyclic ring;   R and R′ are hydrogen;   R12 is hydrogen or C 1 -C 6  alkyl optionally substituted by halogen;   or R12 and any one of R8, R9, R, R′, R10 or R11 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C 1 -C 6  alkyl or C 1 -C 6  alkoxy;   n is 0 or 1; and   R13 is C 2 -C 6  alkenyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy; C 2 -C 6  alkynyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy; or C 2 -C 6  alkylenyl oxide optionally substituted by C 1 -C 6  alkyl.   
     
     
         6 . The method of  claim 1 , wherein
 R1 is hydrogen, or C 1 -C 6  alkyl optionally substituted by hydroxy;   R2 is halogen;   R3 is hydrogen;   R4 is hydrogen;   R5 is halogen;   R6 and R7 stand independently from each other for H, C 1 -C 6  alkyl optionally substituted by hydroxyl, C 3 -C 6  cycloalkyl optionally substituted by halogen or hydroxy, or halogen;   R8, R9, R10 and R11 independently from each other stand for H, or C 1 -C 6  alkyl;   R and R′ are hydrogen;   R12 is hydrogen or C 1 -C 6  alkyl optionally substituted by halogen;   n is 0 or 1; and   R13 is C 2 -C 6  alkenyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy; C 2 -C 6  alkynyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy; or C 2 -C 6  alkylenyl oxide optionally substituted by C 1 -C 6  alkyl.   
     
     
         7 . The method of  claim 1 , wherein
 R1 is hydrogen, or C 1 -C 6  alkyl optionally substituted by hydroxy;   R2 is halogen;   R3 is hydrogen;   R4 is hydrogen;   R5 is halogen;   R6 and R7 stand independently from each other for H, C 1 -C 6  alkyl optionally substituted by hydroxyl, C 3 -C 6  cycloalkyl optionally substituted by halogen or hydroxy, or halogen;   R8 and R9, independently from each other stand for H, or C 1 -C 6  alkyl;   R and R′ are hydrogen;   R12 and any one of R10 or R11 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C 1 -C 6  alkyl or C 1 -C 6  alkoxy;   n is 0 or 1; and   R13 is C 2 -C 6  alkenyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy; C 2 -C 6  alkynyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy; or C 2 -C 6  alkylenyl oxide optionally substituted by C 1 -C 6  alkyl.   
     
     
         8 . The method of  claim 1 , wherein
 R1 is hydrogen, or C 1 -C 6  alkyl optionally substituted by hydroxy;   R2 is halogen;   R3 is hydrogen;   R4 is hydrogen;   R5 is halogen;   R6 and R7 stand independently from each other for H, C 1 -C 6  alkyl optionally substituted by hydroxyl, C 3 -C 6  cycloalkyl optionally substituted by halogen or hydroxy, or halogen;   R8, R9, R10 and R11 independently from each other stand for H, or C 1 -C 6  alkyl;   R and R′ are hydrogen;   R12 is hydrogen or C 1 -C 6  alkyl optionally substituted by halogen;   n is 0 or 1; and   R13 is C 2 -C 6  alkenyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy.   
     
     
         9 . The method of  claim 1 , wherein
 R1 is hydrogen, or C 1 -C 6  alkyl optionally substituted by hydroxy;   R2 is fluoro;   R3 is hydrogen;   R4 is hydrogen;   R5 is halogen;   R6 and R7 stand independently from each other for H, C 1 -C 6  alkyl optionally substituted by hydroxyl, C 3 -C 6  cycloalkyl optionally substituted by halogen or hydroxy, or halogen;   R8 and R9 independently from each other stand for H, or C 1 -C 6  alkyl;   R12 and any one of R10 or R11 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C 1 -C 6  alkyl or C 1 -C 6  alkoxy;   n is 0; and   R13 is C 2 -C 6  alkenyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy; or C 2 -C 6  alkynyl optionally substituted by C 1 -C 6  alkyl or C 1 -C 6  alkoxy.   
     
     
         10 . The method of  claim 1 , wherein
 R1 is C 1 -C 6  alkyl;   R2 is fluoro;   R3 is hydrogen;   R4 is hydrogen;   R5 is fluoro;   R6 and R7 stand independently from each other for H, C 3 -C 6  cycloalkyl, or halogen;   R8, R9, R10 and R11 stand for H;   R12 is hydrogen;   n is 0; and   R13 is C 2 -C 6  alkenyl optionally substituted by C 1 -C 6  alkyl.   
     
     
         11 . The method of  claim 1 , wherein the compound of  claim 1 , or a pharmaceutically acceptable salt thereof, is selected from:
 N-(3-(5-((1-Acryloylazetidin-3-yl)oxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (E)-N-(3-(6-Amino-5-((1-(but-2-enoyl)azetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(6-Amino-5-((1-propioloylazetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(6-Amino-5-((1-(but-2-ynoyl)azetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(5-((1-Acryloylpiperidin-4-yl)oxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (E)-N-(3-(6-Amino-5-(2-(N-methylbut-2-enamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(6-Amino-5-(2-(N-methylpropiolamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (E)-N-(3-(6-Amino-5-(2-(4-methoxy-N-methylbut-2-enamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(6-Amino-5-(2-(N-methylbut-2-ynamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(2-((4-Amino-6-(3-(4-cyclopropyl-2-fluorobenzamido)-5-fluoro-2-methylphenyl)pyrimidin-5-yl)oxy)ethyl)-N-methyloxirane-2-carboxamide;   N-(2-((4-Amino-6-(3-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2(1H)-yl)phenyl)pyrimidin-5-yl)oxy)ethyl)-N-methylacrylamide;   N-(3-(5-(2-Acrylamidoethoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(6-Amino-5-(2-(N-ethylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(6-Amino-5-(2-(N-(2-fluoroethyl)acrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(5-((1-Acrylamidocyclopropyl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (S)—N-(3-(5-(2-Acrylamidopropoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (S)—N-(3-(6-Amino-5-(2-(but-2-ynamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (S)—N-(3-(6-Amino-5-(2-(N-methylacrylamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (S)—N-(3-(6-Amino-5-(2-(N-methylbut-2-ynamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(6-Amino-5-(3-(N-methylacrylamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (S)—N-(3-(5-((1-Acryloylpyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (S)—N-(3-(6-Amino-5-((1-(but-2-ynoyl)pyrrolidin-2H)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (S)-2-(3-(5-((1-Acryloylpyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1(2H)-one;   N-(2-((4-Amino-6-(3-(6-cyclopropyl-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)-5-fluoro-2-(hydroxymethyl)phenyl)pyrimidin-5-yl)oxy)ethyl)-N-methylacrylamide;   N-(3-(5-(((2S,4R)-1-Acryloyl-4-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(6-Amino-5-(((2S,4R)-1-(but-2-ynoyl)-4-methoxypyrrolidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   2-(3-(5-(((2S,4R)-1-Acryloyl-4-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1(2H)-one;   N-(3-(5-(((2S,4S)-1-Acryloyl-4-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(6-Amino-5-(((2S,4S)-1-(but-2-ynoyl)-4-methoxypyrrolidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(5-(((2S,4R)-1-Acryloyl-4-fluoropyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(6-Amino-5-(((2S,4R)-1-(but-2-ynoyl)-4-fluoropyrrolidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (S)—N-(3-(5-((1-Acryloylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (S)—N-(3-(6-Amino-5-((1-propioloylazetidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (S)-2-(3-(5-((1-Acryloylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1(2H)-one;   (R)—N-(3-(5-((1-Acryloylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (R)—N-(3-(5-((1-Acryloylpipendin-3-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(5-(((2R,3S)-1-Acryloyl-3-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(5-(((2S,4R)-1-Acryloyl-4-cyanopyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   and   N-(3-(5-(((2S,4S)-1-Acryloyl-4-cyanopyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide.   
     
     
         12 . The method of  claim 1 , wherein the disease is asthma, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, chronic autoimmune urticaria or an allergic disease. 
     
     
         13 . The method of  claim 11 , wherein the disease is asthma, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, chronic autoimmune urticaria or an allergic disease. 
     
     
         14 . The method of  claim 1 , wherein the compound is
 N-(3-(5-((1-Acryloylazetidin-3-yl)oxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (S)—N-(3-(6-Amino-5-(2-(N-methylacrylamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (S)-2-(3-(5-((1-Acryloylpyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1(2H)-one;   N-(3-(5-(((2S,4R)-1-Acryloyl-4-fluoropyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide,   or   N-(3-(6-Amino-5-(((2S,4R)-1-(but-2-ynoyl)-4-fluoropyrrolidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide.   
     
     
         15 . The method of  claim 1 , wherein the compound is
 N-(3-(5-((1-Acryloylazetidin-3-yl)oxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (S)—N-(3-(6-Amino-5-(2-(N-methylacrylamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide;   (S)-2-(3-(5-((1-Acryloylpyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1(2H)-one;   N-(3-(5-(((2S,4R)-1-Acryloyl-4-fluoropyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide,   or   N-(3-(6-Amino-5-(((2S,4R)-1-(but-2-ynoyl)-4-fluoropyrrolidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide,   
       and wherein the disease is asthma, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome or chronic autoimmune urticaria.